Novavax (NVAX) PT Raised to $295 at JPMorgan Earlier Today, Following Clinical Trial Update
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $8.05 -1.11%
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
JPMorgan analyst Eric Joseph raised the price target on Novavax (NASDAQ: NVAX) to $295.00 (from $215.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
- Lithium Ionic Corp (LTH:CN) PT Lowered to Cdn$2.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
